CG
ORMP icon

Cutler Group’s Oramed Pharmaceuticals ORMP Stock Holding History

Cutler Group’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,713
Closed -$20K – 4456
2022
Q4 		$20K Hold
1,713
– – ﹤0.01% 2225
2022
Q3 		$11K Buy
1,713
+1,213
+243% +$9.82K ﹤0.01% 3080
2022
Q2 		$2K Sell
500
-200
-29% -$1.07K ﹤0.01% 4330
2022
Q1 		$6K Buy
+700
New +$7.17K ﹤0.01% 4030
2017
Q3 		– Sell
-4,904
Closed -$38K – 6466
2017
Q2 		$38K Sell
4,904
-1,200
-20% -$9.05K ﹤0.01% 2774
2017
Q1 		$37K Buy
6,104
+3,000
+97% +$18.7K ﹤0.01% 2694
2016
Q4 		$18K Buy
3,104
+700
+29% +$4.56K ﹤0.01% 3569
2016
Q3 		$17K Sell
2,404
-8,499
-78% -$66.1K ﹤0.01% 3599
2016
Q2 		$90K Sell
10,903
-8,656
-44% -$73.7K ﹤0.01% 1777
2016
Q1 		$130K Buy
19,559
+5,100
+35% +$34.1K 0.01% 1368
2015
Q4 		$123K Buy
+14,459
New +$110K 0.01% 1588

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SIGI
Susquehanna International Group (Ireland) Dublin, Ireland $472M AUM 25.62% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cutler Group's ORMP Position: Q1 2023 in Review

Cutler Group sold out of Oramed Pharmaceuticals (ORMP) in Q1 2023, closing a stake of 1,713 shares — an estimated $20K sold.

Cutler Group first reported a position in ORMP in Q4 2015 and held it in 11 quarters. The position peaked at $130K in Q1 2016. 61 funds tracked by Wall St. Rank hold ORMP as of Q1 2023.

  • Cutler Group reported no remaining Oramed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 1,713 Oramed Pharmaceuticals shares in Q1 2023, an estimated $20K.
  • Cutler Group first reported a position in Oramed Pharmaceuticals in Q4 2015 and held it in 11 quarters.
  • Cutler Group's Oramed Pharmaceuticals position peaked at $130K in Q1 2016.
  • 61 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.